Contrasting Baird Medical Investment (NASDAQ:BDMD) & Thermo Fisher Scientific (NYSE:TMO)

Baird Medical Investment (NASDAQ:BDMD) and Thermo Fisher Scientific (NYSE:TMO) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, analyst recommendations, institutional ownership, earnings, dividends and risk.

Insider & Institutional Ownership

19.8% of Baird Medical Investment shares are owned by institutional investors. Comparatively, 89.2% of Thermo Fisher Scientific shares are owned by institutional investors. 78.9% of Baird Medical Investment shares are owned by company insiders. Comparatively, 0.3% of Thermo Fisher Scientific shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Earnings & Valuation

This table compares Baird Medical Investment and Thermo Fisher Scientific”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Baird Medical Investment	N/A	N/A	N/A	N/A	N/A
Thermo Fisher Scientific	$42.88 billion	5.09	$6.34 billion	$17.31	33.54

Thermo Fisher Scientific has higher revenue and earnings than Baird Medical Investment.

Analyst Recommendations

This is a breakdown of current recommendations for Baird Medical Investment and Thermo Fisher Scientific, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Baird Medical Investment	1	0	0	0	1.00
Thermo Fisher Scientific	0	3	20	1	2.92

Thermo Fisher Scientific has a consensus price target of $616.60, suggesting a potential upside of 6.19%. Given Thermo Fisher Scientific’s stronger consensus rating and higher probable upside, analysts plainly believe Thermo Fisher Scientific is more favorable than Baird Medical Investment.

Risk and Volatility

Baird Medical Investment has a beta of -1.07, indicating that its share price is 207% less volatile than the S&P 500. Comparatively, Thermo Fisher Scientific has a beta of 0.9, indicating that its share price is 10% less volatile than the S&P 500.

Profitability

This table compares Baird Medical Investment and Thermo Fisher Scientific’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Baird Medical Investment	N/A	N/A	N/A
Thermo Fisher Scientific	15.02%	16.97%	8.49%

Summary

Thermo Fisher Scientific beats Baird Medical Investment on 10 of the 11 factors compared between the two stocks.

About Baird Medical Investment

Baird Medical Investment Holdings Ltd. is a medical technology company, which engages in the development and provision of medical devices. It is also involved in the design, development, manufacturing, and sale of microwave ablation medical devices, as well as sale of other medical devices. The company was founded on June 16, 2023 and is headquartered in Guangzhou, China.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, protein detection assays, and instruments; immunodiagnostics develops, manufactures and markets complete bloodtest systems to support the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. It offers products and services through a direct sales force, customer-service professionals, electronic commerce, and third-party distributors under Thermo Scientific; Applied Biosystems; Invitrogen; Fisher Scientific; Unity Lab Services; and Patheon and PPD. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.